Sarepta (SRPT) Therapeutics would need to conduct new studies to show that its Elevidys is safe in order to get its Duchenne muscular dystrophy therapy back on the market, a senior FDA official is quoted by Endpoints News’ Zachary Brennan and Lei Lei Wu as having said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Positive Long-Term Outlook for Sarepta Therapeutics Amid Regulatory Challenges
- Sarepta price target lowered to $35 from $40 at Jefferies
- Sarepta initiated, Spotify upgraded: Wall Street’s top analyst calls
- Roche says Brazilian death unrelated to Elevidys, Bloomberg reports
- Roche says Elevidys benefit-risk in ambulatory patients remains positive